KYORIN LICENSES IMMUNOSUPPRESSANT DRUG TO NOVARTIS
Japan's Kyorin Pharmaceutical Co. said on Thursday it had granted a global license
to Novartis AG to develop and market its immunosuppressant drug KRP-203, in
an effort to speed up the launch of the drug. Under the agreement, Novartis
will have an exclusive license to develop and sell the drug worldwide for use
in treating organ transplant patients. The drug is still at the pre-clinical
stage in Japan.
The Washington Post